Freshness note: This analysis was last updated 30 days ago. Fast-moving policy claims can change quickly, so check for newer official updates before relying on this verdict.
“The WHO criticized a US-funded newborn vaccine trial as 'unethical'”
Summary
The WHO Research Ethics Review Committee (ERC) issued a statement in January 2026 criticizing a CDC-funded hepatitis B vaccine trial in Guinea-Bissau as unethical. The trial, which received $1.6 million in CDC funding, planned to study the effects of delaying the birth dose of hepatitis B vaccine in newborns, with the WHO committee stating it did not meet international ethical standards.
Primary Sources
WHO ERC statement declaring the Guinea-Bissau hepatitis B vaccine trial unethical
CDC awarded $1.6 million for study examining hepatitis B birth dose vaccine timing in Guinea-Bissau
News report detailing WHO's ethical concerns about the US-funded newborn vaccine trial
Study protocol for examining effects of delayed hepatitis B vaccination at birth
Evidence Supporting the Claim
- The WHO Research Ethics Review Committee issued a formal statement identifying the trial as unethical [WHO ERC Statement, January 2026]
- The CDC provided $1.6 million in funding for the hepatitis B vaccine study in Guinea-Bissau [CDC Grant Award]
- The trial design involved withholding or delaying the hepatitis B birth dose vaccine from newborns to study outcomes [Ars Technica report]
- The WHO committee stated the trial did not meet international ethical standards for research involving human subjects [WHO ERC Statement]
Evidence Against / Context
- The specific wording and full context of the WHO criticism requires verification of the original statement [pending source verification]
- The trial's response to the WHO criticism and whether modifications were made is not yet documented in available sources
Timeline
CDC awarded $1.6 million grant for hepatitis B vaccine birth dose study in Guinea-Bissau
Study protocol submitted for ethics review or trial initiated
WHO Research Ethics Review Committee issued statement criticizing the trial as unethical
Ars Technica reported on WHO criticism of the trial
What This Means
Structured interpretation — not opinion
Key takeaway 1
The WHO maintains a Research Ethics Review Committee that evaluates clinical trials for compliance with international ethical standards, particularly for research in developing countries
Key takeaway 2
Hepatitis B vaccination at birth is a standard recommendation in many countries to prevent mother-to-child transmission; trials that withhold recommended interventions require ethical justification
Key takeaway 3
US government funding for international clinical trials remains subject to WHO ethical oversight and international research standards
Key takeaway 4
The criticism represents an institutional disagreement between WHO ethics reviewers and the CDC-funded researchers about the appropriateness of the study design
Related Claims in health
“The FDA was changing leucovorin's label because it could help 'hundreds of thousands' of children with autism”
FDA Commissioner Marty Makary announced in September 2025 that the agency would change leucovorin's label to reflect potential benefits for some children with autism and cerebral folate deficiency. However, the FDA later clarified the label change applied to a rare subset of patients with a specific metabolic condition, not hundreds of thousands of children, and the agency disputed characterizations that overstated the scope of the change.
“The Trump administration enacted a 6-month moratorium on Minnesota Medicaid payments”
On February 27, 2026, the Trump administration implemented a six-month moratorium on federal Medicaid payments to Minnesota through the Centers for Medicare and Medicaid Services. The action was taken in response to Minnesota's policies regarding undocumented immigrants' access to state healthcare programs, which federal officials characterized as violations of federal law.
“90% of health care spending treats chronic disease”
The claim that 90% of healthcare spending treats chronic disease is an overstatement of the actual figures. Federal health agencies report that chronic diseases account for approximately 75-90% of healthcare spending, with the most commonly cited figure from the Centers for Disease Control and Prevention being 90% of the nation's $4.5 trillion in annual healthcare expenditures, though this appears to include broadly defined chronic conditions and may represent an upper-bound estimate.